EHR-guided LDL cholesterol optimization after a heart event
Official title: Electronic Health Record Augmented LDL-Cholesterol Optimization and Control Via Active Lipid Engagement (EHR-LOCALE): A Quality Improvement Implementation Study
Run by University of Alberta · NCT07685639 · Data updated 2026-11-12
A pharmacist-guided program using electronic health records to help adults in Alberta reach LDL goals after a heart event by adjusting medications and ordering tests.
Quick facts
| Study type | Interventional |
|---|---|
| Sex | All |
| Enrollment | 2000 (estimated) |
| Sponsor | University of Alberta Academic / other |
| Locations | 2 sites (Edmonton, Alberta and 1 other locations) |
| Status | Recruiting |
| Started | August 10, 2026 |
| Main results expected | September 2027 |
| Study ends | September 2027 |
| Registry record updated | September 9, 2026 |
| Trial ID | NCT07685639 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults in Alberta who had an acute coronary syndrome and coronary angiography, and can participate in follow-up if assigned to the intervention.
✕Probably not a fit
Patients who do not respond to medication changes or have contraindications to lipid therapies may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This project tests whether an automated, EHR-guided pathway improves LDL-cholesterol target achievement at 6 months compared with usual care. Participants receive pharmacist contact, repeat lipid testing, medication review, adherence support, and treatment escalation per national guidelines. The study aims to see if proactive management after acute coronary syndrome reduces future heart attacks and strokes and makes lipid care more consistent. It identifies eligible patients through the Alberta EHR and delivers targeted optimization as a quality improvement implementation study. Outcomes focus on LDL <1.8 mmol/L at 6 months and overall lipid-management quality.
Why it matters
Potential benefit: If successful, patients may reach LDL targets more reliably, potentially lowering the risk of recurrent heart events.
How similar studies have gone: Previous similar EHR-guided lipid-management initiatives have shown promise in improving treatment intensity and lipid outcomes in post-event care.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Adults over the age of 18 2. Resident of Alberta 3. Individuals hospitalized with an acute coronary syndrome and have undergone coronary angiography. 4. Able to participate in follow-up contact if randomized to the intervention arm Exclusion Criteria: 1\. In-hospital mortality
Where it's running
-
University of Alberta Hospital / Mazankowski Alberta Heart Institute
Edmonton, Alberta, Canada Recruiting -
University of Alberta Hospital / Mazankowski Alberta Heart Institute
Edmonton, Alberta, Canada Recruiting
Study contacts
- Principal investigator: Pishoy Gouda, MD — University of Alberta
- Study coordinator: Canadian VIGOUR Centre
- Email: ehlocale@ualberta.ca
- Phone: (800) 707-9098
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Investigating body fat distribution and its impact on metabolic diseases in Japanese adults
This study looks at how the way body fat is distributed affects the risk of metabolic and heart diseases in Japanese adults.
-
Observational study of achieving LDL targets with Rovazet tablets in dyslipidemia
This study follows patients with dyslipidemia who are prescribed Rovazet to see how well reaching LDL targets works in routine care over 48 weeks.
-
Early Triple Lipid-Lowering Therapy After ACS
This trial tests whether adding bempedoic acid to high-intensity statin and ezetimibe within 72 hours after PCI helps more adults with acute coronary syndrome reach LDL-C goals than the standard two-drug approach.
-
Enlicitide (MK-0616) for adults with high cholesterol in India
This study tests whether enlicitide helps lower bad cholesterol (LDL-C) compared with placebo in adults with hyperlipidemia/hypercholesterolemia.
-
HRS-7249 extension study for people with high triglycerides
This extension study tests whether repeat injections of HRS-7249 are safe and keep triglyceride levels low in adults who previously completed the parent study or have high fasting triglycerides.
-
Bacillus subtilis and Enterococcus faecium Probiotic Plus Lipid-Lowering Therapy for HTG-AP
This trial tests whether adding a probiotic capsule to standard lipid-lowering therapy helps people with mild HTG-AP see lower triglycerides and better recovery.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.